Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06221059
Other study ID # HRS-1780-201
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 2, 2024
Est. completion date April 2025

Study information

Verified date January 2024
Source Shandong Suncadia Medicine Co., Ltd.
Contact Manchen Bao
Phone 0518-82342973
Email manchen.bao@hengrui.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study was to evaluate the efficacy of HRS-1780 tablets or Henagliflozin Proline tablets in patients with chronic kidney disease by evaluating UACR change from baseline to Week 13


Recruitment information / eligibility

Status Recruiting
Enrollment 180
Est. completion date April 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Men and women aged 18-75 years old 2. Body mass index (BMI) =18.0 and <50.0 kg/m2 at the screening visit 3. Subjects treated with an angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB) for at least 3 months without any adjustments to this therapy for at least 4 weeks prior to the screening visit 4. Diagnosed with chronic kidney disease, and the estimated glomerular filtration rate (eGFR) was =30 and <90 mL/min/1.73 m2 calculated using the CKD-EPI formula at the screening visit 5. Urinary albumin/creatinine ratio (UACR) was =300 and <3000 mg/g for at least 2 times on different days detected by the local laboratory; at the screening visit 6. HbA1c <9.0% at the screening visit Exclusion Criteria: 1. A known or suspected allergy to the investigational drug or its components or excipients; 2. Receive a potent inhibitor/inducer of cytochrome P450 3A4 (CYP3A4) within 7 days prior to screening; 3. Within 4 weeks before screening, the following drugs could not maintain the stable regimen: diabetes drugs, hypertension drugs, non-steroidal anti-inflammatory drugs, endothelin receptor antagonists; 4. Receive SGLT-2 or SGLT-1/2 inhibitors within 4 weeks before screening 5. Received glucagon-like peptide-1 receptor agonist (GLP-1RA) within 8 weeks before screening 6. Received systemic glucocorticoid therapy within 3 months before screening 7. Received immunosuppressive drugs or biological agents 8. Received any other study drug treatment within 3 months or 5 half-lives prior to screening 9. Severe hypertension that was not controlled at screening visit or random visit (systolic blood pressure =160 mmHg or diastolic blood pressure =100 mmHg), or systolic blood pressure <90 mmHg 10. Have urinary tract infection or/and genital infection at the screening visit or random visit, or have a history of repeated urinary tract infection or/and genital infection 11. Diagnosed or suspected polycystic kidney disease, lupus nephritis, anti-neutrophil cytoplasmic antibody (ANCA) -associated vasculitis, acute glomerulonephritis, bilateral renal artery stenosis; 12. Acute kidney injury or dialysis treatment within 6 months before screening 13. Received kidney transplant, or plan to receive kidney transplant during the trial

Study Design


Intervention

Drug:
HRS-1780 tablet;Henagliflozin Proline tablet;HRS-1780 tablet placebo ;Henagliflozin Proline tablet placebo
Drug:HRS-1780 tablet Drug:Henagliflozin Proline tablet Drug:HRS-1780 tablet placebo Drug:Henagliflozin Proline tablet placebo

Locations

Country Name City State
China General Hospital of Eastern Theater Command Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Shandong Suncadia Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline to Week 13 in UACR From Baseline to Week 13
Secondary Change From Baseline to Week 13 in UACR category (>20%, >30%, >40%) From Baseline to Week 13
Secondary Change From Baseline to Week 4, Week 7 in UACR From Baseline to Week 4, Week 7
Secondary Change From Baseline to Week 13 in 24-hour urinary protein quantification From Baseline to Week 13
Secondary Change From Baseline to Week 13 in estimated glomerular filtration rate (eGFR). An eGFR was calculated based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. From Baseline to Week 13
Secondary Change From Baseline to Week 13 in blood pressure From Baseline to Week 13
See also
  Status Clinical Trial Phase
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Terminated NCT04043026 - The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
Completed NCT05318014 - Low-protein Formula Supplements in Chronic Kidney Disease N/A
Active, not recruiting NCT06071065 - Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients N/A
Completed NCT02878317 - Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
Not yet recruiting NCT06039254 - Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function Phase 1
Recruiting NCT03160326 - The QUALITY Vets Project: Muscle Quality and Kidney Disease
Withdrawn NCT02885545 - The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial Phase 4
Completed NCT02896309 - The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity N/A
Completed NCT02875886 - DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease Phase 4
Completed NCT02836574 - A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease Phase 2
Completed NCT02756520 - Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Active, not recruiting NCT02483039 - Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization N/A
Terminated NCT02543177 - Optimised Procedure in Patients With NSTEMI and CKD N/A
Completed NCT02992548 - Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease Phase 4
Completed NCT02369549 - Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease Phase 3
Recruiting NCT02205944 - Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes N/A
Active, not recruiting NCT02231138 - Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Phase 4